Current status and future prospects of transdermal estrogen replacement therapy

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Current status and future prospects of transdermal estrogen replacement therapy"

Transcription

1 FERTILITY AND STERILITY Copyright e 1990 The American Fertility Society Vol. 53, No.6, June 1990 Printed on acid-free paper in U.S.A. Current status and future prospects of transdermal estrogen replacement therapy Katherine Miller-Bass, M.D. Eli Y. Adashi, M.D. Division of Reproductive Endocrirwlogy, Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland Transdermal administration of drugs is not new. Babylonian clay tablets from around 600 B.C. give recipes for extracts of herbs mixed with oil and honey that were then rubbed on the stomach of the patient for cure of colic. 1 Although pharmacologic therapy has come a long way since then, there are currently only four drugs approved by the Food and Drug Administration for transdermal administration-scopolamine, nitroglycerin, clonidine, and, most recently, 17,8-estradiol (referred to herein as estradiol [E2]). The scopolamine patch was the first transdermal therapeutic system designed 2 and the others quickly followed. With the development and marketing of Estraderm (transdermal system; Ciba-Geigy Pharmaceutical Co., Summit, NJ), a new route of estrogen-replacement therapy has become available to the obstetrician-gynecologist, and a body of literature pertaining to its use and potential advantages and disadvantages has developed over the past several years. It is the objective of this communication to critically review the literature available, as well as to assess the current and future status oftransdermal E 2 therapy. "Ideal" Estrogen Replacement Therapy: The Concept Versus Reality In designing an optimal form of estrogen replacement for postmenopausal women, the following criteria would have to be met: First, and foremost, such a regimen should return the hormonal milieu, as nearly as possible, to the state that existed before loss of ovarian function. Although not absolutely necessary, the estrogen in question should ideally provide primarily E 2, the major estrogen of the reproductive years, and in amounts capable of maintaining E2 levels within the premenopausal (early follicular) range. Accordingly, the delivery of estrone (E1), or the metabolism ofthe replacement estrogen to E 1, should be such that the ratio of circulating E 2 to E 1 remains at the premenopausal level of;;:: 1. 3 Second, E 2 should be delivered in a sustained controlled fashion, in a manner resembling normal ovarian secretory patterns. Third, the amount of E 2 provided should be sufficient to alleviate vasomotor symptoms, reverse atrophic vaginal changes, prevent osteoporosis, and provide cardioprotection. Significantly, only minimal alteration of hepatic protein synthesis should occur, thereby presumably reducing the incidence of undesired side-effects of estrogen therapy. Finally, the estrogen should be administered in a form that is acceptable to the patient, easy to use, not painful or "messy", free of noticeable side-effects, and with a dosage schedule that is simple to follow. :Keeping these requirements in mind, Table 1 lists various routes of estrogen replacement. A brief review of currently available estrogen preparations follows. As will become apparent below, none of the preparations currently available truly constitutes an ideal form of estrogen replacement therapy. However, much progress has been made to a point that gives rise to the hope that idealized estrogen replacement can perhaps be approximated if not actually realized. ROUTES OF ESTROGEN REPLACEMENT Oral Estrogen-Replacement Therapy Traditionally, estrogens used for replacement therapy in postmenopausal women have been given Vol. 53, No.6, June 1990 Miller-Bass and Adashi Transdermal estrogen replacement therapy 961

2 Table 1 Routes of Estrogen Replacement Oral" Vaginal" Subcutaneous implants Percutaneous Sublingual Intranasal Injectable Transdermal" Indicates forms currently commercially available in the United States. orally. The commonly used preparations, and their standard daily doses, are listed in Table 2. A major disadvantage of oral estrogen replacement, regardless of brand, is immediately evident. Single daily doses result in the delivery of a large bolus of medication, with a gradual decline in blood levels until the next dose is provided. This mode of delivery is in stark contrast to the continuous sustained supply characteristic of ovarian estrogen secretion. Thus, on intuitive grounds alone, all oral estrogen replacement regimens are less than ideal in this regard. Moreover, this form of drug delivery inevitably results in the virtually direct provision of pharmacologic amounts of biologically potent estrogen to the liver, a situation foreign to normally-cycling women whose ovarian-derived estrogens are diluted in the peripheral circulation before reaching the liver at acceptable physiologic concentrations. This "first-pass" effect occurs when oral estrogens are delivered to the liver via the portal circulation after absorption from the intestines, without the benefit of prior metabolism. Significantly, many of the potential deleterious side-effects of estrogen replacement therapy (e.g., hypertension, cholelithiasis) are thought to result from this so-called firstpass phenomenon. 4 5 At first sight, it would therefore appear that alternate, that is, nonoral routes of estrogen administration should reduce the incidence of deleterious side-effects. However, the cardioprotective effect of estrogens may well be, at least in part, the result of this very first-pass phenomenon, presumably through favorable alteration of hepatic lipoprotein biosynthesis. 6 7 Indeed, the increased high-density lipoprotein cholesterol (HDLC) and decreased low-density lipoprotein cholesterol (LDLC) pattern seen in estrogen-users is the lipid pattern associated with a decreased risk of cardiovascular disease. 8 Thus, the favorable effects of oral conjugated equine estrogens on lipoprotein levels could account for the reported cardioprotective effect attributed to oral estrogen administration. In this particular respect, bypassing the liver by using nonoral forms of estrogen therapy may prove to be less than optimal, potentially depriving the patient of cardioprotection. While the above issues are far from resolved at this time, they do serve to demonstrate the difficulties associated with the evaluation of different routes of estrogen replacement. Consequently, the relative utility of oral estrogen replacement therapy as opposed to parenteral forms of treatment remains unclear pending further investigation. Premarin (Wyeth-Ayerst Laboratories, Philadelphia, PA), or conjugated equine estrogens, consists of several estrogen conjugates, primarily E 1 sulfate (>40%) and equilin sulfate (Table 3). This mixture of estrogenic conjugates is derived from the urine of pregnant mares, and as such, represents naturally-occurring estrogens. Sources within the pharmaceutical community estimate that Premarin accounts for approximately 70% of estrogen products sold in the United States. 9 Premarin has been used extensively for estrogen replacement therapy for many years, and its predictable actions have led to its continued use in a variety of situations. Significantly, a large body of literature has been devoted to the study of Premarin, its pharmacokinetics, dose requirements, efficacy, and side-effects. As such, it represents the "gold standard" against which all new preparations are measured. At doses of ~1.25 mg/d, conjugated equine estrogens have been shown to raise serum E 2 levels into the premenopausal early follicular range of 40 to 60 pg/ml 3 at 24 hours after the first dose, and to revert vaginal cytology to a premenopausal state. 4 Although Premarin (~1.25 mg/ d) has been shown to decrease the number of subjectively determined hot flashes, these data are difficult to interpret because of the fact that patients experienced significant symptomatic relief on placebo as well Furthermore, daily doses of mg of Premarin have been conclusively shown to reduce postmenopausal bone loss. 12 Importantly, conjugated equine estrogens are subject to considerable enterohepatic metabolism before entering the bloodstream in a usable form. Thus, E 1 sulfate and other estrogen conjugates contained Table 2 Commonly Used Oral Estrogens Preparation Conjugated equine estrogens Piperazine estrone sulfate Micronized 17 -{J estradiol ethinyl estradiol Brand Pre marin Ogen Estrace Estinyl Dose mg to to to to Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

3 Table 3 Constituents of Premarin (Conjugated Equine Estrogens) Constituent Estrone sulfate Equilin sulfate 17 a-dihydroequilin sulfate Miscellaneous estrogenic conjugates Values are percents. Representation in this preparation undergo deconjugation and reconjugation to glucuronide and sulfate forms in the intestinal mucosa. The conjugated forms are excreted in the urine and the bile, whereas the deconjugated forms are delivered to the liver via the portal circulation where some conversion of E1 to E 2 takes place However, the resulting E 1 levels are significantly higher than those found in premenopausal women, 3 resulting in an E 2 to E1 ratio that is <1, rather than the normal premenopausal ratio of~l. In light of the above, the oral administration of pure E 2 might seem to be the means to overcome the difficulties arising from the administration of a mixture of estrogen conjugates. If given in purified but unmodified form, however, E 2 is poorly absorbed intestinally, rendering small doses ineffective; large doses can lead to gastrointestinal upset.15 This problem has been overcome, to some extent, by the process of micronization wherein the crystal particle size is reduced, thereby increasing its surface area and thus intestinal absorption.15 A single oral dose of 2 mg of micronized E 2 (Estrace; Mead Johnson Laboratories, Evansville, IN) has been demonstrated by Yen and associates16 to significantly elevate serum E 2 concentrations above baseline within 2 hours of administration. Levels well within the premenopausal range are achieved with this standard daily dose Oral micronized E 2 (2 mg/d) has also been shown to reduce the number of subjectively recorded hot flashes in postmenopausal women Thus, micronized E 2 (Estrace) appears, at first glance, to be an appealing alternative to conjugated equine e~trogens. After all, E 2 is the primary ovarian estrogen of the reproductive years, and if given in a relatively pure form might be expected to constitute an ideal form of estrogen replacement therapy. Unfortunately, a series of relative drawbacks results in Estrace falling short of this goal. First, orally-administered Estrace, like oral Premarin, undergoes metabolism in both the gut and the liver. In fact, significant conversion ofe 2 to E 1 by 17/3-hydroxysteroid dehydrogenase (17/3-HSD) occurs in the mucosa of the small bowel.16 Some of the remaining E 2 is subject to a similar fate once it is delivered to the liver via the enterohepatic circulation. Estradiol is also subject to subsequent conjugation to sulfate and glucuronide forms in both the liver and the intestinal mucosa. A large proportion of these conjugates is excreted in the bile, reabsorbed, deconjugated in the intestine, and delivered again to the liver, where conversion to E 2 and E1 takes place Thus, despite the fact that only E 2 is administered, high serum levels of E1 are still the result.16 Specifically, a fourfold increase in the circulating levels of E1 was noted 6 hours after an oral dose (2 mg) of micronized E/6 (Fig. 1). Second, although oral Estrace has proven efficacious in the relief of subjective menopausal symptoms such as sweating and hot flashes, its efficacy in the prevention of osteoporosis and cardiovascular disease has not been studied in a systematic fashion. In fact, the vast majority of patients enrolled in studies concerning cardiovascular risk have been using conjugated equine estrogens as their form of replacement therapy.19 Consequently, direct parallels cannot be drawn with respect to cardiovascular risk in Premarin and Estrace-users. In conclusion, despite its attractiveness as a naturally-occurring estrogen, orally administered Estrace suffers from a number of drawbacks that render it a less-appealing alternative (to oral Premarin therapy) than one might initially suppose. Ethinyl estradiol (EE 2) (Estinyl; Schering Corporation, Kenilworth, NJ) is a synthetic estrogen preparation commonly used as a constituent of combination oral contraceptives (OCs). Biologic effects associated with doses of 10 Jtg/d of EE 2 appear to be similar to the effects of 1.25 mg/d of conjugated estrogens.5 However, the lowest commercially available dose is a 20 Jlg tablet. In a manner similar to orally-administered E 2, EE 2 undergoes conjugation to sulfate and glucuronide forms in the intestinal mucosa and liver. Deconjugation andreconversion to E1 and E 2 occur, and again, as with micronized E 2, result in elevated E1 levels. Ethinyl estradiol is eliminated more slowly from the circulation when compared to E 2, and unlike E 2, its metabolites appear to be excreted in the feces rather than in the urine. 14 Vaginal Estrogen Replacement Therapy Vaginally administered estrogen preparations represent one form of estrogen therapy that might Vol. 53, No.6, June 1990 Miller-Bass and Adasbi Transdermal estrogen replacement therapy 963

4 ORAL VAGINAL Hours Hours Figure 1 Percent change in serum E 2 and E 1 levels after oral and vaginal administration of micronized 17~-estradiol. (Adapted from Yen SSC et al. 16 Reproduced by permission of the publisher.) be expected to bypass the liver and eliminate firstpass metabolism. Currently available vaginal creams are listed in Table 4. The rich vascularization of the vagina, as well as the thinning of the vaginal epithelium that occurs after menopause may aid in the absorption of medications administered vaginally. In fact, vaginal absorption of estrogen is greater in menopausal than in premenopausal women. 20 In contrast to the oral route of administration, wherein E 2 is converted, in large part, to E 1 by 17 {3-HSD in the intestinal mucosa, the vaginal route appears to allow absorption of unmodified E 2 through the (presumptively 17{3-HSDdeficient) vaginal mucosa. Once circulating, some peripheral conversion ofe2 to E 1 will, of course, occur, leading to some elevation of plasma E 1 levels. While this elevation is statistically significant, it does not begin to approach the magnitude of the rise in E 1 levels seen after oral administration of E 2 21 Thus, when E 2 is administered vaginally, the E 2-to-E 1 ratio will remain within the premenopausal range of ~1 (Fig. 1). Using vaginal doses of 0.2 or 2 mg of E 2, Rigg et al. 22 demonstrated significant elevation of the circulating levels of E 2 over baseline, with maintenance of E 2-to-E1 ratios at ~ 1. Hepatic effects were not studied. In contrast, hepatic effects resulting from the vaginal administration of both EE 2 and conjugated equine estrogens have been evaluated. Regrettably, vaginal preparations have not been as successful as might have been hoped in eliminating enhanced liver protein synthesis. While Mandel et al. 20 found significant increases in hepatic protein synthesis only at relatively high doses (1.25 mg and 2.5 mg per day) of vaginally-administered conjugated equine estrogens, such doses were necessary to raise E 2 concen- Table 4 Commonly Used Vaginal Estrogens Preparation Brand Estrogen content/ gram of cream Application schedule Conjugated equine estrogens 17~-estradiol Dienestrol Piperazine estrone sulfate Premarin vaginal cream Estrace DVcream Ogen vaginal cream mg to 4 g/d 3g/wk 6to 18g/wk 2 to 4 g/d 964 Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

5 trations to levels similar to those found in premenopausal women in the early follicular phase. In addition, Goebelsmann et al.23 showed that because of the decreased bioavailability of vaginally-administered EE2, vaginal doses must be three to five fold higher than oral doses to achieve similar suppression of luteinizing hormone (LH) and folliclestimulating hormone (FSH) levels. Unfortunately, liver protein synthesis was significantly increased at these dosages, thus eliminating one of the potential advantages of vaginal administration. However, vaginal cytology has been shown to revert to the premenopausal state after vaginal administration of conjugated equine estrogens at doses as low as 0.3 mg/d,20 an effect associated with only minimal elevations of serum E1 and E2. It would thus appear that vaginal estrogen creams are best used for the reversal of atrophic vaginal changes at doses that are low enough to avoid undesirable systemic side-effects. Vaginal rings that provide continuous E 2 delivery over a period of weeks have been studied and used in some postmenopausal patients for shortterm (3 months) estrogen replacement therapy_i? They appear to maintain E 2 levels within the premenopausal range during use. 17 '24 They are, however, somewhat inconvenient to use, as they must be removed before intercourse. Moreover, these rings are not commercially available at this time. Subcutaneous E 2 Implants In theory, biodegradable subcutaneous E2-containing implants should provide constant and adequate E2 release. These expectations have in fact been met as sustained and controlled release of E 2 using these implants has been demonstrated Disadvantages of subcutaneous E2 implants consist of the initial need for a minor surgical procedure to implant the E 2 pellet under the skin, the consequent difficulties associated with pellet removal should the patient or physician elect to discontinue therapy, the unpredictable duration of reliable estrogen release/7 and the wide variation in E2 levels between patients.26 However, long-term follow-up (6 months) of patients after the subcutaneous implantation of two 25 mg E2 pellets has shown fairly constant serum E2 levels (mean 113 pg/ml) as early as 1 week after initiation of therapy.27 Again, such E2-containing pellets are not commercially marketed at present. Percutaneous E2 Estradiol in ointment form is available in Europe under the trade name Oestrogel (Besins-Iscovesco, Paris, France), and is administered by applying a dose containing 1.5 or 3 mg of E 2 over the abdomen every other day.17 This preparation has the advantage of bypassing hepatic metabolism, and results in a premenopausal E2-to-E1 ratio,28 but can yield extremely variable E2levels some hours after application It is also somewhat cumbersome, as the gel must be spread oyer a large area of skin and allowed to dry before normal activities can be resumed. Sublingual, Intranasal, and Injectable Estrogens Mentioned only for the sake of completeness, both sublingual and intranasal micronized E2 preparations have been used for research purposes. Sublingual administration yields highly variable serum E2 levels, perhaps because of partial swallowing of the medication by the patient, with subsequent hepatic metabolism.17 Neither preparation is commercially available. Premarin for either intramuscular or intravenous injection is available in the United States but appears to be used primarily when oral therapy cannot be used, or in emergency situations. Transdermal Drug Administration Parenteral delivery of E 2 via a transdermal therapeutic delivery system appears to overcome many of the pitfalls noted with other modes of nonoral estrogen replacement. The general benefits of transdermal drug delivery have been well-summarized by Guy et al., 30 and include such attributes as maintenance of a relatively constant drug level within the circulation, lower overall drug dose, reduced frequency of drug dosing, and ease of termination of drug delivery by removal of the system. Additionally, the system is designed so as to control the rate of drug delivery and to minimize variable absorption between patients because of skin differences, such as color or hydration. Whereas there is some evidence to indicate that skin differences have led to differential absorption of transdermal nitroglycerin, 31 there is currently no data to indicate comparable problems with Estraderm (Ciba Geigy Pharmaceutical Co., Summit, NJ) use. The type of estrogen used for replacement therapy may be as important as the route of delivery. In a study designed to examine organ extraction of different classes of estrogens from the circulation, Steingold et al. 32 showed that all classes of estrogens are preferentially taken up by the liver when compared to other tissues (brain and uterus). How- Vol. 53, No.6, June 1990 Miller-Bass and Adashi Transdermal estrogen replacement therapy 965

6 Pharmacokinetics of Transdermal E 2 Figure 2 Estraderm transdermal therapeutic system (Reprinted with permission of Ciba-Geigy Pharmaceuticals, Summit, NJ). ever, oral conjugated estrogens, primarily E 1 sulfate, are poorly taken up by nonhepatic tissues, and must be deconjugated in the liver to be able to exert significant extrahepatic effects. Estradiol, on the other hand, while being preferentially taken up by hepatocytes, can act on other tissues without prior hepatic metabolism. Thus avoiding first-pass metabolism to inactive compounds by the liver will leave significantly more active E 2 available to these tissues. It appears, therefore, that E 2 may be the ideal estrogen for nonoral administration. Estradiol Transdermal Therapeutic System Like most transdermal delivery systems, an Estraderm patch consists of several layers (Fig. 2). The outermost layer, a backing membrane, serves to hold the contents within the reservoir and serves as a waterproof covering for the system. Underneath it lies the drug reservoir that contains E 2 dissolved in alcohol (ethanol). An alcohol, rather than an aqueous solvent, is used because E 2 is approximately 100,000 times more soluble in alcohol than in water. Below the reservoir is the control membrane, a plastic film that controls the rate of both alcohol and E 2 diffusion out of the reservoir and into the next layer, the adhesive layer. Not only does this latter layer serve to hold the entire system in place on the patient, but in concert with the overlying control membrane, acts as a further determinant of the rate at which E 2 leaves the system to come into contact with the skin. In effect, the two layers (control membrane and adhesive layer) act like a pair of electrical resistors in series to control the rate of E 2 diffusion from the reservoir. 33 The bottom layer is simply a protective liner that is removed before application. The E 2 contained in the reservoir is delivered at a relatively constant rate through the control membrane. 3 Two systems are currently available on the market, measuring 10 cm 2 and 20 cm 2 and delivering 0.05 mg and 0.10 mg of E 2/d, respectively. The system is applied to the lower abdomen or buttocks, and changed twice weekly, as recommended by the manufacturer. Although the pharmacokinetics of Estraderm have not been extensively studied, Powers et al. 3 have compared delivery rates and steady-state levels of E 2 after administration of oral and transdermal E 2 Using Estraderm systems delivering 0.025, 0.05, and 0.10 mg/d, these investigators demonstrated (within 4 hours of patch application) serum E 2 levels of approximately 30 pg/ml for the mg patch, and 70 and 100 pg/ml for the 0.05 and 0.10 mg patches, respectively. Peak circulating E 2 levels were reached at about 8 hours after patch application, and steady-state levels during a single 72-hour wearing period were maintained at 40 and 75 pg/ml for the 0.05 and 0.10 mg/d patches, respectively. Significantly, these E 2 levels are well within the normal range for premenopausal women in the early follicular phase. 3 In addition, longerterm evaluation (i.e., 3 weeks of wearing the 0.05 mg/d Estraderm systems) revealed mean serum E 2 levels of 37.6 pg/ml, a value that was, again, similar to that seen in the early follicular phase of premenopausal women. 3 Daily measurement of urinary E 2 conjugates revealed average levels comparable with those produced during the follicular phase of premenopausal subjects-1, 2, and 4 1-Lg/g of creatinine for 0.025, 0.05, and 0.10 mg/d of Estraderm, respectively. Using a 0.10 mg/d patch, Stancyzk et al. 27 demonstrated mean serum E 2 levels of 52 to 89 pg/ml over a 24-week period, similar to the levels noted by Powers et al. 3 over a 72-hour wearing of the 0.10 mg/d patch. Additional information regarding the absorption oftransdermal E 2 immediately after patch application has been published by Haas et al. 34 Hourly E 2 levels obtained during the 8 hours after application of a 0.05 mg patch revealed peak serum levels of 91 pg/ml at only 2hours after application. A statistically significant decrease in mean serum E 2 levels (from 88 pg/ml to 48 pg/ml) was observed 8 hours after removal of the patch. This level was, however, still significantly greater than serum E 2 levels noted in patients who received placebo only. Since the above studies represent the only detailed studies of the pharmacokinetics of Estraderm presently available, a number of questions concerning Estraderm absorption remain unanswered. As mentioned before, skin differences, specifically racial differences, have been shown to affect absorption. Indeed, the overall absorption of transdermal nitroglycerin was reduced in black as compared with white subjects. 31 This phenomenon 966 Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

7 is probably because of differences in the thickness of the stratum corneum, which is the rate-limiting layer of the epidermis in transcutaneous absorption. Significantly, this skin layer is particularly thick in blacks. Given that some 12% of females entering the menopause will be black, this difference in stratum corneum thickness could conceivably affect rates of Estraderm absorption in this population. Moreover, both patient age and site of drug application have been reported to alter transdermal absorption of medications.35 However, Schenkel et al.,36 using urinary E 2 excretion as a measure of E2 uptake from and 0.05 mg/ destraderm patches, found no statistically significant differences in E 2 absorption when patches were applied to several skin sites-abdomen, lateral thorax, buttocks, lower back, or upper arm. Only placement of the patches on the upper thigh resulted in significantly decreased absorption (85%) when compared with the abdominal site (100%). These and related issues are thus likely to benefit from closer scrutiny. Effects of Estraderm on Circulating Estrogen Levels There seems to be no disagreement in the literature in regard to the ability of Estraderm (~0.05 mg/d) to ensure serum E2 levels typical of those seen in premenopausal women in the early to midfollicular phase As noted earlier, steady-state E2 levels of approximately 40 to 75 pg/ml are maintained during the 72-hour wearing periods of the 0.05 mg and 0.10 mg/d patches These steady-state values are similar to those seen 24 hours after the third daily oral dose of Premarin 1.25 mg or Estrace 2 mg, for which the levels attained are 31 and 66 pg/ml, respectively. However, in contrast to the marked increase in serum E1levels seen with oral estrogen administration (increased from pretreatment values of approximately 30 to 35 pg/ml to steady-state values of 150 to 334 pg/ml), Estraderm administration resulted in only minor elevations in serum E1, with levels reaching the 30 to 60 pg/ml range for both the 0.05 and 0.10 mg/d patches These minor increases probably reflect minimal in situ conversion of transdermal E 2 by skin as well as limited systemic metabolism, resulting in the maintenance of a premenopausal E2/E1 ratio of ~1P Effects of Estraderm on Serum Gonadotropin Levels Serum FSH and LH have been shown to decrease to levels that are significantly different from postmenopausal baseline values after the administration of Estraderm at both the 0.05 and 0.10 mg/d doses A decrease in serum LH levels occurs as early as 5 hours after application in patients using a 0.05 mg/ d patch and levels that are statistically significantly lower than those seen in patients using placebo are observed within 8 hours. 34 The decreases seen with the 0.05 mg/d patch are equivalent to those produced by the daily oral administration of either mg Premarin38 or 2 mg micronized E2.3 The 0.1 mg/d patch is approximately equivalent to 1.25 mg/d of oral Premarin in terms of gonadotropin suppression.15 None of the estrogen preparations studied, oral or transdermal, proved capable of suppressing serum FSH or LH to premenopausal levels at any dose.3 38 This incomplete gonadotropic suppression is thought to reflect the fact that other ovarian factors, such as progesterone40 and inhibin,41 may be necessary for more complete negative feedback on gonadotropin release. Effects of Estraderm on Vasomotor Symptoms From the patient's point of view, the most important result of estrogen replacement therapy is the amelioration of symptoms, especially hot flashes. Standard doses of Estraderm have been shown to reduce the number of subjectively and objectively measured hot flashes. Steingold et al.42 demonstrated a significant reduction in the number of objectively documented hot flashes in postmenopausal women treated with transdermal E2 at doses of ~0.05 mg/d. Hot flashes were measured over a 10-hour period by continuous monitoring of finger temperature and skin resistance, hot flashes being defined as notation of subjective symptoms by the patient occuring within 5 minutes of an objectively measured increase in skin temperature of > l.ooc and a decrease in skin resistance. Interestingly, a linear reduction in the number of hot flashes per hour was noted with increasing doses of E 2 provided by the Estraderm patch. This decrease was statistically significant for patients using a system providing ~0.05 mg/d.42 Based on a linear regression analysis of hot flashes/h versus circulating levels of E 2 achieved, the authors predicted that E2 levels of around 60 pg/ml should yield a 50% reduction in hot flashes, whereas levels of 122 pg/ml would be expected to completely abolish hot flashes42 (Fig. 3). The authors point out, however, that considerable individual variation was noted among patients regarding number of hot flashes Vol. 53, No.6, June 1990 Miller-Bass and Adashi Transdermal estrogen replacement therapy 967

8 c 1.60 Q) E ~ >.S 8 = ~ " I... 1! "' 0.40 : g "'.. "- 0 I R = p<0.001 Serum Estradiol During Treatment (pg/ml) Figure 3 Linear regression analysis of hot fiashes/h versus circulating serum E 2 levels during Estraderm treatment. (From Chetkowski et al. 38 Reprinted by permission of the publisher.) that occurred at any given E 2 level. Haas et al.34 have published similar results demonstrating a 50% reduction in objectively measured hot flashes at E 2 levels of 73 pg/ml in patients using a 0.05 mg/d patch for 6 weeks, while Laufer et al.37 observed a decrease from to 0.25 objectivelymeasured hot flashes/h in patients using an undisclosed dose of Estraderm for 3 weeks. The data of Padwick et al.39 support the above work, showing a decrease in the number of subjectively recorded hot flashes in patients using the 0.05 mg/d system. Further reduction of hot flashes occurred with continued use. No significant differences in the weekly number of subjectively recorded hot flashes were noted between patients treated with Estraderm 0.10 mg/d and those treated with or 1.25 mg Premarin/dY A decrease in other menopausal symptoms, including sleep disturbances, irritability, and anxiety has also been demonstrated after Estraderm administration,39 there being no statistically significant differences in the frequency of these symptoms between Estraderm users and those using Premarin.43 Thus, Estraderm appears to provide satisfactory relief of hot flashes in most patients and is at least comparable to Premarin in this respect. Effects of Estraderm on Urogenital Atrophy Another menopausal symptom of considerable concern to patients is that of vaginal discomfort or dryness secondary to atrophic or senile vaginitis. Both oral and vaginal estrogen preparations have been shown to revert vaginal cytology back to a state that is akin to that seen in premenopausal women, i.e., an increased percentage of superficial cells and a decreased percentage of parabasal cells A number of studies have now shown similar beneficial effects of Estraderm on vaginal cytology at both the 0.05 mg and 0.10 mg/d doses Patients using Estraderm 0.10 mg/d did not differ significantly in the number or severity of vaginal complaints recorded in a daily diary when compared with patients using Premarin or 1.25 mg/dy While patients using the 0.05 mg/d patch demonstrated a decrease in the number of complaints related to vaginal dryness, this decrease failed to reach statistical significance.39 It appears, then, that Estraderm (0.10 mg/d) is equivalent to oral conjugated equine estrogens (0.625 mg/d) in affording relief from this menopausal symptom. Estraderm at the 0.05 mg/d dose may be ineffective in this regard, though increased improvements in vaginal complaints were rated with each successive cycle using the 0.05 mg/d patch.39 Effects of Estraderm on Endometrium Administration of Estraderm 0.05 mg/d, either cyclically (without a progestogen) or continuously (combined with progestogen) has been shown to have a proliferative effect on endometrium as evidenced by the occurrence of vaginal bleeding and the finding of an increased number of endometrial b. wpsws. yw. ld' mg pro l'" 11era t' 1ve en d orne t num.. 34,44,45 The addition of a progestational agent for 12 days of each cycle in patients using Estraderm continuously, markedly decreased the incidence of random or breakthrough bleeding when compared with patients using Estraderm only in a cyclic (3 wk/mo) fashion. The majority of patients using Estraderm continuously with norethindrone added during the last 12 days of the regimen experienced bleeding only at the completion of the progestational therapy or slightly thereafter.44 When compared with patients using oral conjugated equine estrogens (1.25 mg/d) in cyclic fashion with medroxyprogesterone acetate, patients using cyclic transdermal E 2 (0.05 mg/d) and medroxyprogesterone acetate experienced significantly fewer days of spotting and/or bleeding.45 Of the 28 subjects included in the aforementioned studies who underwent endometrial biopsy while using transdermal E 2, only one subject developed endometrial hyperplasia. This was classified as mild adenomatous hyperplasia and was obtained on biopsy after 6 weeks of treatment with Estraderm 0.05 mg/d without the addition of a progestogen Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

9 80001 ::l l 121 Renin Substrate (ng/ml). II [t] ~ j II ~ OJ EF Base TBG l~g/ml) II rn CBG Bindmg Copoc1ty ~ :~J tfm ~ 625 EF Base line Estraderm Premarin line Estraderm Premarin (mcg/24 hrl (mg) tmcg/24 hr) {mgl Figure 4 Effects of Estraderm and Premarin administration on circulating liver proteins (EF =early follicular phase levels). (From Chetkowski et al. 38 Reprinted by permission of the publisher.) Effects of Estraderm on Protein Synthesis by the Liver It has generally been predicted that transdermal E 2 administration could possibly avoid the enhanced hepatic protein synthesis seen with oral estrogens, thereby eliminating possible adverse sideeffects. Indeed, the administration of Estraderm 0.05 mg or 0.10 mg/d resulted in minimal elevation of hepatic protein levels when compared with the impact of oral Premarin administered in doses of mg or 1.25 mg/d Levels of sex-hormonebinding globulin, thyroxine-binding globulin, cortisol-binding globulin, and renin substrate were not increased above baseline at any of the four doses (0.025 mg, mg, 0.10 mg, and 0.20 mg/d) of Estraderm used (Fig. 4). In addition, the circulating levels of the above-mentioned proteins were not statistically significantly different from levels in premenopausal controls Padwick et al., 39 administering 0.05 mg/d of Estraderm for 3 months to 12 postmenopausal and perimenopausal patients, noted no significant difference in either plasma renin substrate levels, or in plasma renin activity at the end of the treatment period. The data of Laufer et al. 37 support these findings, demonstrating no significant changes in levels of renin substrate, thyroxine-binding globulin, sex-hormone-binding globulin, or cortisol-binding globulin after 3 weeks of treatment with Estraderm systems (no dose given), and Haas and colleagues 34 showed no significant differences in renin substrate levels or activity or in aldosterone levels after 6 weeks of therapy with Estraderm 0.05 mg/d. Taken together, these studies support the premise that transdermal E 2 administration does indeed avoid the enhancement of liver protein synthesis noted with oral estrogen replacement, at least on a short-term (3 month) basis. Effects of Estraderm on Blood Pressure Though few investigators have actually addressed the effects of Estraderm on blood pressure, some data do exist. Haas et al. 34 observed no statistically significant differences from baseline in either systolic or diastolic blood pressure of patients who had been using Estraderm 0.05 mg/d for 6 weeks. Pad wicket al. 39 observed decreases in both systolic and diastolic blood pressure in patients using 0.05 mg/d patches over a 3-month period; however, these decreases were not maintained throughout the study period, and were present only at some visits. In sum, then, Estraderm appears to have minimal, if any, effect on blood pressure. Effects of Estraderm on Serum Lipid Levels The effects of Estraderm on serum lipid levels and the long-term significance ofthese effects have been the subject of much controversy. While treatment with 1.25 mg/ d of oral Pre marin for 28 days resulted in small but significant decreases in both serum cholesterol and LDL as well as a concomitant increase in serum HDL, all doses ofestraderm studied over the same time period had no effect on any of these parameters Changes in lipids seen with mg/d Premarin did not reach statistical significance. 38 Accordingly, the HDL/LDL ratio increased significantly in those patients receiving Premarin 1.25 mg/d, but did not in those patients using transdermal E 2 systems. 38 DeLignieres et al. 47 have observed a similar lack of effect of percutaneous E 2 on serum lipid levels. Specifically, patients receiving daily doses of 3 mg of percutaneous E 2 for 2 months displayed no changes in the circulating levels of either total cholesterol, LDL, or HDL cholesterol. 47 However, in a double-blind study ofestraderm 0.05 mg/d versus placebo, Haas et al. 34 noted small but significant decreases in serum LDL in the Estraderm users. Unfortunately, placebo users also experienced a decrease in LDL levels during the 6-week study period. Significantly, the above studies involved only short-term use of transdermal or percutaneous E 2 The use ofestraderm 0.10 mg/d has been shown to result in significantly increased HDL levels after 24 weeks of administration. 27 As total cholesterol Vol. 53, No.6, June 1990 Miller-Bass and Adashi Transdermal estrogen replacement therapy 969

10 levels did not change over this same time period, there was a corresponding decrease in the total cholesterol/hdl ratio. Low-density lipoprotein levels remained unchanged from baseline. In a more extensive study involving 2 years of percutaneous E 2 (3 mg/d) and oral micronized progesterone (200 mg/d, 12 d/cycle), Jensen et al. 48 observed somewhat different results. At the end of the first year, patients using percutaneous E 2 only for 28 days each month demonstrated statistically significant decreases in both total cholesterol and LDL cholesterol when compared with their initial values and when compared with patients using placebo. These differences were maintained after the addition of oral progesterone for 12 days each cycle during the 2nd year of therapy. In patients receiving E 2, HDL levels remained unchanged at the completion of the 1st year of treatment, but showed a small but significant increase 6 months after the addition of oral progesterone. It appears then that administration of these percutaneous E 2 preparations over a longer period of time will eventually result in small but significant favorable changes in the serum lipoprotein patterns in a manner similar to that seen with oral Premarin use. Effects of Estraderm on Clotting Factors Judd 46 and Chetkowski et al. 38 have observed no effect of either Estraderm (0.025 mg, 0.05 mg, 0.10 mg, 0.20 mg/d) or Premarin (0.625 mg or 1.25 mg/d) on any of three clotting factors measured: fibrinopeptide A, antithrombin III levels and activity, and high-molecular-weight fibrinogen. Decreases in antithrombin-iii levels have been demonstrated with oral micronized E 2 or E 2 valerate therapy, but again, no change in the circulating levels of this clotting factor was noted with percutaneous E 2 use. 46 These observations support the contention that the transdermal administration of ~ should have no measurable effects on clotting factors and that it is unlikely to lead to a hypercoagulable state. Effects of Estraderm on Bone Economy Long-term bone loss as assessed by single-photon absorptiometry has been shown to be inhibited by oral estrogen administration, the minimum dose of conjugated equine estrogens necessary to achieve this effect being mg/dp However, the effects of Estraderm administration on bone loss have not as yet been thoroughly studied. * i.2o Urinary Calcium/Creatinine Ratio line * Estraderm (mcg/24 hrl I * Premarin (mgl Figure 5 Effects of Estraderm and Premarin administration on urinary calcium excretion and urinary calcium/creatinine and hydroxyproline/creatinine ratios (EF = early follicular phase levels). (From Chetkowski et al. 38 Reprinted by permission ofthe publisher.) The above notwithstanding, limited studies are available on the effect of Estraderm on urinary calcium and hydroxyproline excretion. Urinary calcium/creatinine and hydroxyproline/creatinine excretion ratios have been extensively employed as an indirect measure of bone resorption. Urinary calcium excretion has been shown to increase after menopause, presumably reflecting increased bone resorption that can result in osteoporosis. 49 Similarly, given a collagen-free diet, most of the hydroxyproline found in the urine is derived from bone, its excretion increasing during the postmenopausal period. 50 Unfortunately, studies concerning the effect of Estraderm on these parameters have differed somewhat. On the one hand, all studies documented higher urinary calcium and hydroxyproline excretion in postmenopausal women as compared with their premenopausal counterparts, a trend reduced after the administration of transdermal E However, using an unspecified dose of Estraderm, Laufer et al. 37 failed to show any statistically significant decrease in either urinary calcium/creatinine or hydroxyproline/creatinine ratios, 37 while Chetkowski et al. 38 demonstrated statistically significant decreases in the urinary calcium/creatinine ratios only, at all doses of Estraderm tested 38 (Fig. 5). 970 Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

11 Percent Change Individual Changes Mean Changes 20 8 n=6 16 n=14 T 6 12 in 8 I Spinal BMD I 4... ) I I I II --~--- I Months of Treatment Figure 6 Changes in spinal bone mineral density with Estraderm (0.05 mg/d). (From Ribot et al.52 Reproduced with the permission of the publisher.) 4 2 Selby and Peacock, 51 on the other hand, observed significant decreases in urinary calcium/creatinine and hydroxyproline/creatinine ratios in patients treated with Estraderm 0.05 mg/d. The exact reason for such variable results is not readily apparent, but may be due in part to the small numbers of patients involved (11 to 20) or the extremely short time of Estraderm administration (3 to 4 weeks). No studies involving actual bone-density measurements of patients using Estraderm have yet been published, but preliminary results of a 2-year study of the effects of Estraderm on postmenopausal bone loss by Ribot et al.52 are encouraging. Thirteen patients underwent measurement of lumbar spine bone mineral density by dual photon absorptiometry after 6 and 12 months of treatment with Estraderm 0.05 mg/d. No significant decrease in bone mineral density was noted after 6 months of treatment, and a small but statistically significant increase was noted at 12 months (Fig. 6). These results suggest that Estraderm will prove effective in preventing postmenopausal bone loss. Side-Effects and Patient Compliance Patient compliance during use of E 2 transdermal systems has been good in nearly all studies, and few side-effects have been noted. As previously outlined, patients achieve good relief of vasomotor and other menopausal symptoms, while experiencing no significant increase in other systemic side-effects, such as nausea or breast tenderness, often associated with estrogen therapy.39 When compared with Premarin users, the incidence of the aforementioned side-effects was no different.43 In a group of 12 patients who used a total of 252 patches during the study period, only 6 instances of poor adhesion of the patch were reported.39 Patients carried out normal activities, including bathing and showering, and seldom encountered difficulties with the system. Local skin reaction to the patch, usually consisting of erythema, nearly always characterized as mild, has also been reported39 43 and rarely resulted in discontinuation of the patch by the patient. 53 For some patients, the use of an Estraderm patch might prove to be a very desirable means of estrogen replacement therapy. This is particularly true for patients who have difficulty swallowing pills or experience nausea when using oral estrogens. On the other hand, the need for progestational therapy in combination with Estraderm in patients with an intact uterus means that the patient will still need to take pills for some days each month. Such a combination of two completely different modes of drug delivery may be unacceptable to some patients. Although instances of poor patch adhesion appear to be infrequent,38 this could still prove to be a problem in patients who are extremely physically active. Perspiration and frequent showering could Vol. 53, No.6, June 1990 Miller-Bass and Adashi Transdermal estrogen replacement therapy 971

12 very well lead to poor adhesion and the need to replace patches more often than every 3 days. On a practical level, it may prove difficult for some patients to remember when they need to change their patch. Daily medication becomes a habit, whereas changing a patch twice weekly is less automatic. The manufacturer has attempted to overcome this by providing a "wheel" on each Estraderm package that serves as a reminder of when the patch must be changed. When set to the day of the week when the first patch is applied, it automatically indicates the day when the patch must be changed for a new one. Still, many patients may find this too inconvenient and opt for more traditional means of therapy. SUMMARY The efficacy of transdermal E 2 in restoring serum E 2 levels to the premenopausal range and in affording relief of menopausal symptoms seems well-established. Importantly, Estraderm is providing a controlled sustained supply of E 2, the prevalent premenopausal estrogenic species. In doing so, Estraderm approximates normal physiology by serving, in effect, in the capacity of an artificial ovary. The minimal elevation of liver proteins seen in patients treated with Estraderm may aid in avoiding some of the complications traditionally seen with oral estrogen-replacement therapy. The medication appears to be well-tolerated, easy to use, and side effects are few. Comparative studies suggest that Estraderm 0.05 and 0.10 mg/d are approximately equivalent to Premarin and 1.25 mg daily37 respectively, an observation supported by others.46 However, there is some evidence that the 0.05 mg/d patch is not as effective as mg/d Premarin in relieving some vaginal complaints,39 and that a higher Estraderm dose (0.10 mg/d) may be necessary in some patients. The effect(s), if any, of transdermal E 2 administration on serum lipids, and the relevance of such changes to long-term cardiovascular morbidity, have not been well defined. In fact, the data on the actual effects of oral estrogen administration on cardiovascular morbidity seem less than clear-cut at this point in time. The vast majority of the literature pertaining to estrogen replacement therapy and cardiovascular disease in women does seem to imply that estrogen administration may, at the least, have no statistically significant impact on cardiovascular risk, and may in fact be cardioprotective.19 In a comprehensive review of the literature on this subject, Bush and Barrett-Connor19 make the statement that "estrogens have powerful effects on certain biologic parameters, the alteration of which could influence cardiovascular disease risk," and further conclude that if this protective effect is indeed real, it would make a very compelling reason for routine estrogen replacement therapy. Currently, however, the issue remains controversial, and no long-term studies involving cardiovascular morbidity and mortality in women using transdermal E2 exist. As noted earlier, perhaps long-term administration ofestraderm would result in changes in HDL and LDL patterns similar to those seen with oral Premarin. Even if this were not the case, Estraderm administration may have beneficial effects on long-term cardiovascular endpoints, and these endpoints must be evaluated before reasonable decisions can be made regarding the appropriateness of this form of estrogen therapy. Similarly, the question as to the efficacy of Estraderm in the prevention of postmenopausal osteoporosis remains unanswered. Despite the decreases in several indirect markers of bone resorption seen with Estraderm administration, and the encouraging results of Ribot et al.52 showing increased bone mineral density after 1 year of Estraderm use, additional long-term studies are clearly essential if Estraderm is to become an acceptable form of estrogen-replacement therapy. What About the Future? With its ability to significantly increase serum E2levels with minimal side-effects, there is no reason why Estraderm could not be used in many of the situations where oral estrogens ani now used. The wearing of a patch might be more appealing and more convenient for some patients, and could, in the long run, prove more cost-effective. Estraderm has also been successfully applied toward the establishment and maintenance of pregnancy in women without ovarian function through the use of donor eggs Preliminary studies by Gangar et al of a transdermal system containing a combination of E2 and norethindrone indicate that it may eliminate some of the shortcomings associated with the administration of transdermal estrogen alone such as the necessity for the concomitant administration of oral progestins in patients with an intact uterus. This preparation has important implications for future contraceptive therapy as well. Additionally, the success of Estraderm may pave 972 Miller-Bass and Adashi Transdermal estrogen replacement therapy Fertility and Sterility

13 the way for the transdermal administration of other steroid preparations. Transdermal testosterone therapy has already been used successfully in the treatment of male hypogonadism. 5 8 Assuming that Estraderm can be shown to be unequivocally cardioprotective and capable of arresting osteoporosis, it is likely to provide a highly attractive form of estrogen replacement. This possibility is likely to be further enhanced if and when longer-acting patches can be devised. Thus, there is little doubt that the development and use of the transdermal therapeutic system has opened doors to a new era in hormonal replacement therapy. REFERENCES 1. Thompson CJS: The Mystery and Art of Apothecary. Bungay, Suffolk, England, R. Clay and Sons, 1929, p 8 2. Shaw JE, Urquhart J: Transdermal drug administrationa nuisance becomes an opportunity. Br Med J 283:875, Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA: Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17~-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol152:1099, Geola FL, Frumar AM, Tataryn IV, Lu KH, Hershman JM, Eggena P, Sambhi MP, Judd HL: Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 51:620, Mandel FP, Geola FL, Lu JKH, Eggena P, Sambhi MP, Hershman JM, Judd HL: Biological effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol 59:673, Cedars MI, Judd HL: Normal routes of estrogen administration. Obstet Gynecol Clin North Am 14:269, Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler A, Rifkind BM: Estrogen use and all-cause mortality. JAMA 249:903, Gordon T, Castelli WP, Hjortland MC, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 62:707, Ernst W: District Sales Manager, Wyeth-Ayerst Pharmaceuticals. Personal communication 10. Coope J, Thomsen JM, Potter L: Effects of "natural estrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 4:139, Campbell S, Whitehead M: Estrogen therapy and the menopausal syndrome. Clin Obstet Gynecol4:31, Lindsay R, Hart DM, Clark DM: The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63:759, Lievertz RW: Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol156:1289, Bolt HM: Metabolism of estrogens-natural and synthetic. Pharmacol Ther 4:155, Martin PL, Burnier AM, Greaney MO: Oral menopausal therapy using 17~-estradiol. Obstet Gynecol39:771, Yen SSC, Martin PL, Burnier AM, Czekala NM, Greaney MO, Jr, Callantine MR: Circulatory estradiol, estrone and gonadotropin levels following the administration of orally active 17~-estradiol in postmenopausal women. J Clin Endocrinol Metab 40:518, Nichols KC, Schenkel L, Benson H: 17~-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv 39(suppl):230, Callantine MR, Martin PL, Bording OT, Warner PO, Greaney MO, Jr: Micronized 17~-estradiol for oral estrogen therapy in postmenopausal women. Obstet Gynecol46:37, Bush TL, Barrett-Connor E: Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 7:80, Mandel FP, Geola FL, Meldrum DR, Lu JHK, Eggena P, Sambhi MP, Hershman JM, Judd HL: Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 57:133, Schiff!, Tulchinsky D, Ryan KJ: Vaginal absorption of estrone and 17~-estradiol. Fertil Steril28:1063, Rigg LA, Hermann H, Yen SSC: Absorption of estrogens from vaginal creams. N Engl J Med 298:195, Goebelsmann V, Mashchak CA, Mishell DR, Jr: Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol151:868, Stumpf PG: Selecting constant serum estradiol levels achieved by vaginal rings. Obstet Gynecol67:91, Thorn MH, Collins WP, Studd JW: Hormonal profiles in postmenopausal women after therapy with subcutaneo~s implants. Br J Obstet Gynecol88:416, Lobo RA, March CM, Goebelsmann U, Koauss RM, Mishell DR: Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol138:714, Stancyzk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, and Lobo RA: A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Dbstet Gynecol159:1540, Holst J, Cajander S, Carlstrom K, Dauber MG, and von Schoultz B: Percutaneous estrogen replacement therapy: effects on circulating estrogens, gonadotropins and prolactin. Acta Obstet Gynecol Scand 62:49, Lyrenas S, Carlstrom K, Backstrom T, and vonschoultz B: A comparison of serum estrogen levels after percutaneous and oral administration of estradiol-17~. Br J Obstet Gynaecol88:181, Guy RH, Hadgraft J, Bucks DAW: Transdermal drug delivery and cutaneous metabolism. Xenobiotica 17:325, Zwicke DL, Niazi I, Reeves WC, Wagel SS: Reduced transcutaneous nitroglycerin absorption in blacks. Circulation 74(suppl II):543, Steingold KA, Cefaeu W, Partridge W, Judd HL, Chandhuri G: Enhanced hepatic extraction of estrogens used for replacement therapy. J Clin Endocrinol Metab 62:761, Good W: CIBA-GEIGY Pharmaceuticals. Personal communication 34. HaasS, Walsh B, Evans S, Krache M, Ravnikar V, and Schiff I: The effect of transdermal estradiol on hormone and metabolic dydnamics over a six-week period. Obstet Gynecol 71:671, Barry BW: Properties that influence percutaneous absorption: In Dermatological Formulations: percutaneous Absorption, Edited by BW Barry. New York, Marcel Dekker, Inc., 1983, p Schenkel L, Barlier D, Riera M: Transdermal absorption of Vol. 53, No.6, June 1990 Miller-Bass and Adasbi Transdermal estrogen replacement therapy 973

Estrogens and progestogens

Estrogens and progestogens Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.

More information

Appendix: Reference Table of HT Brand Names

Appendix: Reference Table of HT Brand Names Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Routes of drug administration

Routes of drug administration Routes of drug administration Definition:- A route of administration in pharmacy is the path by which a drug is taken into the body. Classification:- The various routes of administrations are classified

More information

Bioidentical Hormone Preparations - History of Development

Bioidentical Hormone Preparations - History of Development Bioidentical Hormone Preparations - History of Development The use of the terminology BIOIDENTICAL HORMONE therapy has aroused much controversy and heated debate over the past 20 years, often with much

More information

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be made with input from your healthcare provider. After the decision has been made to take HT, many women don t realize

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Menopause. Medicines To Help You

Menopause. Medicines To Help You Medicines To Help You Menopause Use this guide to help you talk to your doctor, pharmacist, or nurse about your hormone medicines. The guide lists all of the FDA-approved products now available to treat

More information

By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University

By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University Cessation of menstruation as a result of the aging process of or surgical removal of the ovaries; change

More information

presents with Ken Sekine, MD

presents with Ken Sekine, MD presents Pioneering Technologies For Pellet Hormone Therapy Lifestyle Based Medicine A Primer for Clinicians with Ken Sekine, MD Dr. Sekine is a board certified OB-GYN who has been in private practice

More information

Female Sexual Hormones Indications and Therapy

Female Sexual Hormones Indications and Therapy Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses

More information

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW. PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN: Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex

More information

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34

More information

Bioidentical Hormones: Just the Facts

Bioidentical Hormones: Just the Facts Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!

More information

Hormone Products for Postmenopausal Use in the United States and Canada

Hormone Products for Postmenopausal Use in the United States and Canada Hormone Products for Postmenopausal Use in the United States and Canada Copyright The North American Menopause Society October 25, 2011 Table 1. Oral ET products for postmenopausal use in the United States

More information

Pharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration

Pharmaceutics I صيدالنيات 1. Unit 2 Route of Drug Administration Pharmaceutics I صيدالنيات 1 Unit 2 Route of Drug Administration 1 Routs of Drug administration The possible routes of drug entry into the body may be divided into two classes: Parenteral Rout Enteral Rout

More information

Menopause management NICE Implementation

Menopause management NICE Implementation Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

Pharmacokinetics I. Dr. M.Mothilal Assistant professor Pharmacokinetics I Dr. M.Mothilal Assistant professor DRUG TRANSPORT For a drug to produce a therapeutic effect, it must reach to its target and it must accumulate at that site to reach to the minimum

More information

Hormone Replacement Therapy For Men Consultation Information

Hormone Replacement Therapy For Men Consultation Information Hormone Replacement Therapy For Men Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones

More information

Topical Preparations

Topical Preparations Topical Preparations One of the functions of the skin is to protect the internal body components against the external environment and thus to control the passage of chemicals into and out of the body.

More information

Year: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy

Year: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull

More information

Menopause & HRT. Matt McKenna Elliot Davis

Menopause & HRT. Matt McKenna Elliot Davis Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea

More information

Orals,Transdermals, and Other Estrogens in the Perimenopause

Orals,Transdermals, and Other Estrogens in the Perimenopause Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Reproductive System. Testes. Accessory reproductive organs. gametogenesis hormones. Reproductive tract & Glands

Reproductive System. Testes. Accessory reproductive organs. gametogenesis hormones. Reproductive tract & Glands Reproductive System Testes gametogenesis hormones Accessory reproductive organs Reproductive tract & Glands transport gametes provide nourishment for gametes Hormonal regulation in men Hypothalamus - puberty

More information

Public Assessment Report Scientific discussion. Gelistrol (estriol) SE/H/906/01/DC

Public Assessment Report Scientific discussion. Gelistrol (estriol) SE/H/906/01/DC Public Assessment Report Scientific discussion Gelistrol (estriol) SE/H/906/01/DC This module reflects the scientific discussion for the approval of Gelistrol. The procedure was finalised at 2010-07-28.

More information

Conflict of Interest Disclosure. No conflict of interest to disclose

Conflict of Interest Disclosure. No conflict of interest to disclose Denise Gruccio Paolucci DNP, CRNP, PNP-BC Division of Endocrinology/Diabetes Diagnostic and Research Growth Center Turner Syndrome Program The Children s Hospital of Philadelphia Conflict of Interest Disclosure

More information

Disclosures. Objec7ves 9/9/15. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC.

Disclosures. Objec7ves 9/9/15. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC Disclosures None Objec7ves Discuss terminology of bio- iden7cal, synthe7c and natural hormones.

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years

More information

OVERVIEW OF MENOPAUSE

OVERVIEW OF MENOPAUSE OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause

More information

Apples & Oranges Synthetic vs. Bio-Identical Studied Under the Nation s Greats in Hormone Therapy! Salt Lake City Dr. Neal Rouzier Orlando Dr. Sangeeta Pati Naples Dr. Daved Rosensweet And finally Dallas

More information

Menopausal Management: What Has Changed?

Menopausal Management: What Has Changed? Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning

More information

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK 2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail

More information

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now

More information

For topical use only. Not for oral, ophthalmic, or intravaginal use.

For topical use only. Not for oral, ophthalmic, or intravaginal use. DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid

More information

Menopause & HRT. Rosie & Alex. Image:

Menopause & HRT. Rosie & Alex. Image: Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P

Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P presents Converting Patients from Conventional Pioneering Technologies For to Bioidentical Lifestyle Based Medicine Hormone Therapy with Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P

More information

Difference between vagifem and yuvafem

Difference between vagifem and yuvafem Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone

More information

Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List

Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and

More information

AROMASIN 25mg (Tablets)

AROMASIN 25mg (Tablets) APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate

More information

Current Topics in Hormone Replacement Therapy

Current Topics in Hormone Replacement Therapy Current Topics in Hormone Replacement Therapy Corey R. Babb, D.O., FACOOG, IF, NCMP Clinical Assistant Professor of Obstetrics and Gynecology Director of the Oklahoma State University Center for Women

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Ohio Northern University HealthWise. Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018

Ohio Northern University HealthWise. Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018 Women s Health Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018 Let Your Body Empower You! National Women s Health Week Polycystic Ovary Syndrome Page 2 Breast

More information

Data Shows Reduction in Frequency and Severity in Hot Flashes in as Early as 14 Days

Data Shows Reduction in Frequency and Severity in Hot Flashes in as Early as 14 Days Newly Published Menopause Study: Bioidentical and FDA Approved Divigel (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated with Menopause Data Shows Reduction

More information

Hormone Restoration and Support

Hormone Restoration and Support Hormone Restoration and Support As a doctor with a strong interest in functional medicine, I strive to help my patients to achieve optimal health in the best ways I know how. This encompasses a combined,

More information

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest

More information

Hormone Treatments and the Risk of Breast Cancer

Hormone Treatments and the Risk of Breast Cancer Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause

More information

BioIdentical Hormone Replacement Therapy for Women

BioIdentical Hormone Replacement Therapy for Women BioIdentical Hormone Replacement Therapy for Women Bio-Identical Hormones are manufactured hormone products from soy or yam. They are changed in a laboratory so that the hormones produced are identical

More information

Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System)

Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System) Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle (Estradiol Transdermal System) Minivelle now approved for prevention of postmenopausal osteoporosis at all doses New 0.025

More information

Female sex steroids and contraceptives agents

Female sex steroids and contraceptives agents Female sex steroids and contraceptives agents Female Sex Hormones Sex hormones produced by the gonads are necessary for conception, embryonic maturation, and development of primary and secondary sexual

More information

Lab Tests Made Simple

Lab Tests Made Simple Body Fluids Commonly Used for Testing Steroid Hormones Blood Serum (venipuncture) Plasma (venipuncture) Capillary Blood (finger/heel stick) Urine Saliva Limitations of Hormone Testing in Different Body

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed

More information

Breast Cancer Risk in Patients Using Hormonal Contraception

Breast Cancer Risk in Patients Using Hormonal Contraception Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation

More information

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D

HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions

More information

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test

More information

Pharmacokinetic overview of Ortho Evra /Evra

Pharmacokinetic overview of Ortho Evra /Evra FERTILITY AND STERILITY VOL. 77, NO. 2, SUPPL 2 FEBRUARY 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Pharmacokinetic

More information

Determination of bioavailability

Determination of bioavailability Pharmaceutics 2 Bioavailability Bioavailability is the rate and extent to which an administered drug reaches the systemic circulation. For example, if 100 mg of a drug is administered orally and 70 mg

More information

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014 Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits

More information

North American Menopause Society (NAMS)

North American Menopause Society (NAMS) North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College

More information

Basic Concepts of TDM

Basic Concepts of TDM TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.

More information

Before you prescribe

Before you prescribe Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT

More information

Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts

Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can

More information

The Physical and Emotional Toll of Hormone Imbalance for Women. Sally Brooks

The Physical and Emotional Toll of Hormone Imbalance for Women. Sally Brooks The Physical and Emotional Toll of Hormone Imbalance for Women Sally Brooks 2 A hormone imbalance happens when your body produces too much or too few hormones needed for optimal health. When that happens,

More information

Menopause Symptoms and Management: After Breast Cancer

Menopause Symptoms and Management: After Breast Cancer Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a

More information

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013 Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Imvexxy (estradiol) NEW PRODUCT SLIDESHOW

Imvexxy (estradiol) NEW PRODUCT SLIDESHOW Imvexxy (estradiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Imvexxy Generic name: Estradiol Pharmacological class: Estrogen Strength and Formulation: 4mcg, 10mcg; vaginal inserts Manufacturer: TherapeuticsMD,

More information

Balancing Hormone Function in Women By Meghna Thacker, NMD

Balancing Hormone Function in Women By Meghna Thacker, NMD Balancing Hormone Function in Women By Meghna Thacker, NMD Hormone function is central to health and well being in both men as well as women. A problem encountered with any one endocrine gland can lead

More information

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics

More information

ORILISSA (elagolix) oral tablet

ORILISSA (elagolix) oral tablet ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Is Extract ERr731 from the Rheum Rhaponticum Effective in Relieving Menopausal Symptoms in Women Aged 45 to 55 Years of Age?

Is Extract ERr731 from the Rheum Rhaponticum Effective in Relieving Menopausal Symptoms in Women Aged 45 to 55 Years of Age? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Extract ERr731 from the Rheum Rhaponticum

More information

Management of Menopausal Symptoms

Management of Menopausal Symptoms Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of

More information

Hormone Replacement Therapy For Women

Hormone Replacement Therapy For Women Hormone Replacement Therapy For Women Consultation Information www.urologyaustin.com Biological Aging and Hormones As we age, a natural degeneration and aging of organs causes the levels of our hormones

More information

22/09/2014. Menopause Management. Menopause. Menopause symptoms

22/09/2014. Menopause Management. Menopause. Menopause symptoms Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):

More information

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this... PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes

More information

Page 1 of 8 Official reprint from UpToDate www.uptodate.com 2012 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.

More information

This includes bone loss, endometrial cancer, and vasomotor symptoms.

This includes bone loss, endometrial cancer, and vasomotor symptoms. Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to

More information

Estrogens & Antiestrogens

Estrogens & Antiestrogens Estrogens & Antiestrogens Menstrual cycle... Changes and hormonal events Natural estrogens: Estadiol >> Estrone > Estriol Ineffective orally Synthesis: From cholesterol ; role of aromatase enzyme in converting

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway

More information

A Practitioner s Toolkit for the Management of the Menopause

A Practitioner s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash

More information

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method. 1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains

More information

Orilissa (elagolix) NEW PRODUCT SLIDESHOW

Orilissa (elagolix) NEW PRODUCT SLIDESHOW Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie

More information

Principles of Drug Action. Intro to Pharmacology: Principles of Courework Drug Action Intro to Pharmacology

Principles of Drug Action. Intro to Pharmacology: Principles of Courework Drug Action Intro to Pharmacology Principles of Drug Action Intro to Pharmacology: Principles of Courework 102.3 Drug Action Intro to Pharmacology Directions Read the PPT and complete R.E.A.D. Assignment. There are videos embedded within

More information

2016. All Rights Reserved. 1

2016. All Rights Reserved. 1 Pamela W. Smith, M.D., MPH, MS Copyright 2016 The suggested dosages are for educational purposes only. They are suggestions for patients with normal renal and hepatic function. They are based upon my research

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen? CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,

More information

Hormonal Changes Following Low-Dosage Irradiation of Pituitary and Ovaries in Anovulatory Women

Hormonal Changes Following Low-Dosage Irradiation of Pituitary and Ovaries in Anovulatory Women Hormonal Changes Following Low-Dosage Irradiation of Pituitary and Ovaries in Anovulatory Women Further Studies A. E. Rakoff, M.D. Tms PRESENTATION is a second progress report in a long-term study of the

More information

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service

More information

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St

More information

Topic 24: Estrogens and Female Reproductive Drugs

Topic 24: Estrogens and Female Reproductive Drugs Topic 24: Estrogens and Female Reproductive Drugs I. Contraceptives A. Estrogen-Progestin Contraceptives Note all of these drugs contain one estrogen (listed first) and one progestin Drug to know: ethinyl

More information